Detalhe da pesquisa
1.
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
N Engl J Med
; 387(17): 1557-1568, 2022 10 27.
Artigo
Inglês
| MEDLINE | ID: mdl-36094839
2.
Survival with Cemiplimab in Recurrent Cervical Cancer.
N Engl J Med
; 386(6): 544-555, 2022 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35139273
3.
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(9): 989-1001, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37591293
4.
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.
Lancet Oncol
; 24(11): 1196-1205, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37875144
5.
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Lancet
; 397(10274): 592-604, 2021 02 13.
Artigo
Inglês
| MEDLINE | ID: mdl-33581821
6.
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 848-857, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34000246
7.
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
N Engl J Med
; 379(4): 341-351, 2018 07 26.
Artigo
Inglês
| MEDLINE | ID: mdl-29863979
8.
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.
J Am Acad Dermatol
; 90(2): 414-418, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-37839734
9.
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
J Immunother Cancer
; 12(3)2024 03 11.
Artigo
Inglês
| MEDLINE | ID: mdl-38471711
10.
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
J Thorac Oncol
; 18(6): 755-768, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37001859
11.
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Nat Med
; 28(11): 2374-2380, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36008722
12.
Response to Letter to the Editor.
J Thorac Oncol
; 18(7): e74-e75, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-37348997
13.
Functional activation of heat shock factor and hypoxia-inducible factor in the kidney.
J Am Soc Nephrol
; 13(8): 2094-101, 2002 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-12138141